Anita T. Shaffer | Authors

Articles

CASPIAN Update Shows Ongoing Survival Benefit With Durvalumab in ES-SCLC

May 30, 2020

“Importantly, the separation among the curves seems to be observed over time and, indeed, survival at 2 years improves from 14% [of participants] in the control arm to 22% on the experimental arm. The magnitude of the benefit is very similar and very consistent across all the prespecified subgroups of patients analyzed, including those treated with cisplatin or those patients with liver or brain metastases.”

Dynamic Tumor Cell Profiling Technique Moves Therapy Beyond Genomics

November 30, 2019

A technique involving BH3 profiling is emerging as a promising drug discovery tool for assessing whether a tumor is primed for cell death and would respond to anticancer therapy, according to a presentation at the 2019 Association for Molecular Pathology Annual Meeting and Expo.

Resistance Mutations Pose Complex Challenges for Pathologists

November 13, 2019

The emergence of resistance mutations in patients with cancer who receive targeted therapies is an expected development that will require new diagnostic methods of identifying the mechanisms through which these alterations occur, according to Fei Dong, MD, during the 2019 Association for Molecular Pathology Annual Meeting.

Study Depicts Complexity of MET Exon 14 Mutation Testing

November 11, 2019

The identification of MET exon 14 skipping mutations in patients with non–small cell lung cancer presents a complex diagnostic challenge that requires both DNA and RNA analysis, according to results of a University of Michigan pathology study.

Dynamic Tumor Cell Profiling Technique Correlates With Therapy Responses

November 08, 2019

A technique involving BH3 profiling is emerging as a promising drug discovery tool for assessing whether a tumor is primed for cell death and would respond to anticancer therapy, according to a presentation at the 2019 Association for Molecular Pathology Annual Meeting.

Findings From Two Studies Show Positive Results From Neoadjuvant Immunotherapy in NSCLC

June 03, 2019

Findings from 2 studies of patients with operable early-stage non–small cell lung cancer showed preoperative immunotherapy had positive activity and favorable toxicity, according to a presentation at the 2019 ASCO Annual Meeting, and phase III clinical trials are already testing these stratgies.